2025 Japan Atrial Fibrillation Market Revenue Opportunities Report
Description
The 2025 Japan Atrial Fibrillation Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Atrial Fibrillation Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the atrial fibrillation market in Japan are Johnson & Johnson, Boston Scientific Corporation, CardioFocus, Inc., and Bristol Myers Squibb. Johnson & Johnson has introduced advanced electrophysiology devices like the VARIPULSE™ Pulsed Field Ablation system integrated with the CARTO™ 3 mapping system to improve AF ablation procedures in Asia-Pacific, including Japan. Boston Scientific is a key player in Asia-Pacific atrial fibrillation surgery markets, notably focused on minimally invasive ablation technologies in Japan. CardioFocus has expanded its partnership with Japan Lifeline Co., Ltd., to distribute its HeartLight X3 balloon ablation catheter system in the Japanese market. Bristol Myers Squibb recently launched a new anticoagulant targeting atrial fibrillation in Japan, emphasizing safer pharmacologic therapies for AF patients.
Together, these companies drive Japan’s growing AF market, fueled by an aging population and high stroke risk from AF, which accounts for about 20% of strokes there. The market in Japan is projected to reach over $3.5 billion by 2030, growing at a CAGR of 11.6%, with pharmacological treatments leading in revenue. These firms combine device innovation, clinical partnerships, and pharmacotherapy to meet rising demand for advanced AF management in Japan’s expanding healthcare infrastructure.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Atrial Fibrillation Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the atrial fibrillation market in Japan are Johnson & Johnson, Boston Scientific Corporation, CardioFocus, Inc., and Bristol Myers Squibb. Johnson & Johnson has introduced advanced electrophysiology devices like the VARIPULSE™ Pulsed Field Ablation system integrated with the CARTO™ 3 mapping system to improve AF ablation procedures in Asia-Pacific, including Japan. Boston Scientific is a key player in Asia-Pacific atrial fibrillation surgery markets, notably focused on minimally invasive ablation technologies in Japan. CardioFocus has expanded its partnership with Japan Lifeline Co., Ltd., to distribute its HeartLight X3 balloon ablation catheter system in the Japanese market. Bristol Myers Squibb recently launched a new anticoagulant targeting atrial fibrillation in Japan, emphasizing safer pharmacologic therapies for AF patients.
Together, these companies drive Japan’s growing AF market, fueled by an aging population and high stroke risk from AF, which accounts for about 20% of strokes there. The market in Japan is projected to reach over $3.5 billion by 2030, growing at a CAGR of 11.6%, with pharmacological treatments leading in revenue. These firms combine device innovation, clinical partnerships, and pharmacotherapy to meet rising demand for advanced AF management in Japan’s expanding healthcare infrastructure.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
